CuraTeQ
CuraTeQ Biologics is a Hyderabad-based, fully integrated biosimilar developer and wholly-owned subsidiary of Aurobindo Pharma, manufacturing monoclonal antibody biosimilars across oncology, immunology, haematology, osteology, endocrinology, and ophthalmology for healthcare providers, hospitals, and oncology clinics in 50+ countries.
- Company typePrivate
- Founded2016
- HeadquartersHyderabad, India
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What CuraTeQ does
CuraTeQ Biologics Private Limited is a fully integrated biosimilar company founded in 2016 and headquartered in Hyderabad, India, operating as a wholly-owned subsidiary of Aurobindo Pharma, one of the world's largest pharmaceutical groups. The company develops, manufactures, and commercializes monoclonal antibody (mAb) biosimilars and recombinant biologics across oncology, immunology, osteology, haematology, endocrinology, and ophthalmology. As of 2025–2026, CuraTeQ has four commercially launched products — Bevqolva (bevacizumab), Dazublys (trastuzumab), Dyrupeg (pegfilgrastim), and Zefylti (filgrastim) — and a pipeline of 14+ biosimilar programs, with marketing authorizations secured from EMA, UK MHRA, Health Canada, and India CDSCO.
CuraTeQ's technology platform spans clone-to-commercial biosimilar development, including proprietary mammalian cell line development using CHO and HEK293 expression systems, orthogonal analytical characterization with ICH-compliant method validation, scalable upstream and downstream bioprocess development supported by Design-of-Experiment optimization and Process Analytical Technology, and end-to-end clinical development from Phase I PK/PD comparability studies through Phase III confirmatory efficacy trials. Manufacturing is anchored by a 10,000L (4 x 2,500L) GMP-certified bioreactor facility in Sangareddy, Hyderabad, which received EMA GMP certification following an April 2024 inspection covering mammalian and microbial drug substance manufacturing, prefilled syringe and vial filling, packaging, and QC testing. The company claims its therapies have reached 26 million+ patients globally across 50+ countries.
CuraTeQ operates a B2B distribution model selling biosimilar products to healthcare providers, hospitals, and oncology clinics. Revenue is generated through direct product sales (notably in India via CDSCO authorization and in Canada via Health Canada NOCs) and through out-licensing arrangements, exemplified by the March 2026 partnership with Germany's STADA Arzneimittel AG for EU commercialization of two EMA-approved biosimilars in France and Germany. The company leverages Aurobindo Pharma's global distribution network, regulatory affairs infrastructure, and procurement relationships for market access, and reports Phase 3 comparability success in 608-patient omalizumab and 446-patient denosumab studies. Specific pricing is not publicly disclosed and is negotiated with institutional buyers and government procurement channels.
CuraTeQ firmographics
Firmographics- Name
- CuraTeQ
- Legal name
- CuraTeQ Biologics Private Limited
- Website
- https://curateqbio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- CuraTeQ Biologics is a Hyderabad-based, fully integrated biosimilar developer and wholly-owned subsidiary of Aurobindo Pharma, manufacturing monoclonal antibody biosimilars across oncology, immunology, haematology, osteology, endocrinology, and ophthalmology for healthcare providers, hospitals, and oncology clinics in 50+ countries.
- Ownership category
- akta.pro rank
CuraTeQ industry classification
Industry- Product category
- Biosimilars / Biopharmaceutical Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)
- akta.pro secondary industries
- Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF)
Keywords
Where CuraTeQ is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices3 records
Markets served
CuraTeQ business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales
Revenue model
- Biosimilar Product Sales: CuraTeQ generates revenue through sales of approved biosimilar products — Bevqolva (bevacizumab), Dyrupeg (pegylated filgrastim), Zefylti (filgrastim), and Dazublys (trastuzumab) — to healthcare providers and oncology clinics in regulated markets including India, UK, EU, and Canada. Revenue is driven by expanding commercial launches and market penetration across 50+ countries.
- Out-licensing / Regional Partnerships: CuraTeQ out-licenses rights to approved biosimilars to regional commercialization partners. STADA Arzneimittel AG was granted rights to commercialize two EMA-approved biosimilars under new brand names in select EU countries including France and Germany, providing upfront and milestone-based licensing revenue.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
CuraTeQ product offering
Product offeringCore offering
CuraTeQ Biologics develops, manufactures, and commercialises biosimilar monoclonal antibodies and recombinant biologics for oncology, immunology, haematology, endocrinology, and ophthalmology indications. The company operates a fully integrated clone-to-commercial platform covering mammalian cell line development (CHO and HEK293), scalable bioprocess development, GMP-certified manufacturing at 10,000L bioreactor scale, and clinical development through Phase III. Its launched portfolio includes Bevqolva (bevacizumab), Dazublys (trastuzumab), Dyrupeg (pegfilgrastim) and Zefylti (filgrastim), with a pipeline of 14+ biosimilar programs and approvals from EMA, MHRA, Health Canada and CDSCO.
Product overview
CuraTeQ Biologics is a fully integrated biosimilar company and wholly owned subsidiary of Aurobindo Pharma, headquartered in Hyderabad, India. The company develops, manufactures, and commercializes biosimilar products with a portfolio of 14+ biosimilar programs across oncology, haematology, immunology, endocrinology, and ophthalmology therapeutic areas. Their launched products include Bevqolva (bevacizumab), Dazublys (trastuzumab), Dyrupeg (pegylated filgrastim), and Zefylti (filgrastim). The company operates end-to-end capabilities from R&D through GMP manufacturing with 10,000L bioreactor capacity, serving 50+ countries through global regulatory approvals from EMA, MHRA, Health Canada, and CDSCO.
Differentiator
Problem solved
Functional benefit
Brands
- Bevqolva: Bevacizumab biosimilar for treatment of multiple cancers including colorectal and lung cancer
- Dyrupeg
- Zefylti
- Dazublys
Products and services
- Bevqolva (BP01) — bevacizumab biosimilar Bevacizumab biosimilar for treatment of metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or peritoneal cancer. Marketed to healthcare providers and oncology clinics in India, UK, EU, and Canada.
- Dazublys (BP02) — trastuzumab biosimilar Trastuzumab biosimilar for HER2-positive metastatic and early breast cancer and gastric cancer. Marketed in the EU with CHMP positive opinion and EC marketing authorisation.
- Dyrupeg (BP14) — pegfilgrastim biosimilar Pegylated filgrastim biosimilar for reduction of neutropenia duration and febrile neutropenia incidence in cancer patients treated with cytotoxic chemotherapy. Available as 6 mg prefilled syringe.
- Zefylti (BP13) — filgrastim biosimilar Filgrastim biosimilar for treatment of neutropenia and mobilisation of peripheral progenitor cells. Available in 30 MU/0.5 mL and 48 MU/0.5 mL prefilled syringe formulations.
- BP11 — omalizumab biosimilar Omalizumab biosimilar referencing Xolair for chronic spontaneous urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps. Phase 3 trial completed with 608 patients across Europe and India.
- BP16 — denosumab biosimilar Denosumab biosimilar referencing Prolia for treatment of postmenopausal osteoporosis and bone disorders. Phase 3 trial completed across 40 sites in five European countries.
Quantifiable outcome
- 26 million+ patients impacted globally through CuraTeQ's biosimilar therapies
- +3 more outcomes
Companies that use CuraTeQ
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles2 records
CuraTeQ technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
CuraTeQ partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- STADA Arzneimittel AGcoreCuraTeQ Biologics partnered with German pharmaceutical company STADA Arzneimittel AG to market and distribute two EMA-approved biosimilars in select EU territories. STADA commercializes the products under new brand names in select EU countries including France and Germany. The partnership aims to expand CuraTeQ's market presence and boost revenue in the European region. This follows the broader industry trend of biosimilar companies leveraging established regional players for commercialization.
- BioFactura IncminorCuraTeQ Biologics mutually terminated its licensing agreement with US-based BioFactura Inc for BFI-751, a proposed biosimilar of ustekinumab (Stelara), effective December 27, 2025. The agreement, originally executed on July 7, 2023, was terminated following CuraTeQ's strategic portfolio prioritisation. The termination is not expected to have any material impact on Aurobindo's broader biosimilars strategy. This was a development and commercialisation support partnership that did not progress to commercial launch.
Scale indicators11 records
Recent moves7 records
Expansion highlights6 records
CuraTeQ competitors and assessment
Company assessmentDirect peers
- Zydus Cadila (Zydus Lifesciences): Indian pharmaceutical major with biosimilar programs including adalimumab and oncology biologics. Comparable in developing biosimilars targeting both Indian and global markets with integrated manufacturing.
- Dr. Reddy's Laboratories: Indian pharma major with a dedicated biologics arm developing and commercializing biosimilars including rituximab and other mAbs. Comparable in end-to-end biosimilar capabilities and emerging-markets distribution focus.
- Celltrion: Korean biopharmaceutical company with one of the broadest commercial biosimilar mAb portfolios globally (rituximab, trastuzumab, infliximab). Direct competitor in oncology biosimilars with established EMA/FDA approvals.
- Samsung Bioepis: Biosimilar-focused subsidiary of Samsung Group developing mAb biosimilars (etanercept, infliximab, adalimumab, ranibizumab) for global markets. Comparable in integrated biosimilar development and large-scale mammalian cell manufacturing.
- Alvotech: Pure-play biosimilar company developing mAb biosimilars (adalimumab, ustekinumab, aflibercept) targeting regulated markets with vertically integrated manufacturing. Closely comparable business model and regulatory strategy.
- Coherus Biosciences: US-based biosimilar commercializer with approved biosimilars including pegfilgrastim and trastuzumab, plus immunology assets. Comparable portfolio overlap, particularly in G-CSF and oncology biosimilars targeting regulated markets.
- Biocon Biologics: India-based, fully integrated biosimilar developer and manufacturer with a comparable portfolio of mAb biosimilars (trastuzumab, bevacizumab, filgrastim, pegfilgrastim). Most directly comparable peer given shared geography, scale of manufacturing, and overlapping therapeutic focus.
- Intas Pharmaceuticals (Accord BioPharma): India-headquartered generics player with a biosimilars division (Accord BioPharma) commercializing biosimilars including pegfilgrastim in regulated markets. Comparable vertically integrated biosimilar operations and India-based manufacturing.
Broad incumbents
- Amgen: Originator of key reference biologics (bevacizumab-equivalent franchise, denosumab, filgrastim) with growing biosimilars portfolio through Amjevita and others. Competes both as reference-product holder and biosimilar maker.
- Pfizer (biosimilars division): Large diversified pharma with a meaningful biosimilars portfolio including bevacizumab, trastuzumab, and rituximab biosimilars. Competes in same molecules but as part of broader portfolio, not a pure-play.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
CuraTeQ social profiles
Digital presenceCuraTeQ compliance and trust
Trust signalCompliance5 records
CuraTeQ financial estimates
Financial estimateRevenue estimate
Valuation estimate
CuraTeQ leadership team
Management profileNumber of profiles
Profiles2 records
CuraTeQ funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CuraTeQ M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CuraTeQ
What does CuraTeQ do?
CuraTeQ Biologics develops, manufactures, and commercialises biosimilar monoclonal antibodies and recombinant biologics for oncology, immunology, haematology, endocrinology, and ophthalmology indications. The company operates a fully integrated clone-to-commercial platform covering mammalian cell line development (CHO and HEK293), scalable bioprocess development, GMP-certified manufacturing at 10,000L bioreactor scale, and clinical development through Phase III. Its launched portfolio includes Bevqolva (bevacizumab), Dazublys (trastuzumab), Dyrupeg (pegfilgrastim) and Zefylti (filgrastim), with a pipeline of 14+ biosimilar programs and approvals from EMA, MHRA, Health Canada and CDSCO.
Is CuraTeQ a public or private company?
CuraTeQ is a private company. It is classified as corporate owned and is currently operating.
When was CuraTeQ founded?
CuraTeQ was founded in 2016. It employs 501 to 1,000 people.
Where is CuraTeQ based?
CuraTeQ is headquartered in Hyderabad, India, in the Asia region.
How does CuraTeQ make money?
Two revenue lines are on record. Biosimilar Product Sales are the primary driver. The others are out-licensing / Regional Partnerships.
Who are CuraTeQ's main competitors?
Direct peers on record are Zydus Cadila (Zydus Lifesciences), Dr. Reddy's Laboratories, Celltrion, Samsung Bioepis, Alvotech, Coherus Biosciences, Biocon Biologics and Intas Pharmaceuticals (Accord BioPharma). Broad incumbents are Amgen and Pfizer (biosimilars division).
Does CuraTeQ have an API?
No public API is recorded for CuraTeQ.
What industry is CuraTeQ in?
CuraTeQ's product category is Biosimilars / Biopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAAAKAA, Biologic API/Drug Substance Manufacturing Services, with a secondary code of HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream). Its NAICS code is 325414 and its SIC code is 2836.